Company news

Exelixis, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Exelixis Announces $550 Million Share Repurchase Program

March 19, 2023

Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit

March 12, 2023

Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer

March 1, 2023

Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors

February 12, 2023

Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

February 6, 2023

Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023

January 23, 2023

Exelixis Announces Update on Patent Litigation with MSN Laboratories

January 18, 2023

Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023

January 7, 2023

Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 — Presentation to be webcast on www.exelixis.com —

January 2, 2023

Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer

December 21, 2022

Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy

December 7, 2022

Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022

December 7, 2022

Exelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022

November 29, 2022

Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline

November 2, 2022

Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update

October 31, 2022

Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα

October 31, 2022

Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan

October 31, 2022

Exelixis Announces Promising Initial Dose-Escalation Results from the First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022

October 25, 2022

Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022

October 17, 2022

Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 Trial

October 3, 2022

Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022

September 9, 2022

Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022

September 6, 2022

Exelixis To Webcast Fireside Chats as Part of Investor Conferences in September

September 5, 2022

Exelixis Announces Second Quarter 2022 Financial Results and Provides Corporate Update

August 8, 2022

Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

July 25, 2022

Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer

July 10, 2022

Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies

July 6, 2022

Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference

July 4, 2022

Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer

June 20, 2022

Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies

June 15, 2022

Exelixis To Webcast Fireside Chats as Part of Investor Conferences in June

May 30, 2022

Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022

May 25, 2022

Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022

May 25, 2022

Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update

May 9, 2022

Exelixis To Webcast Fireside Chats as Part of Investor Conferences in May

May 3, 2022

Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

May 2, 2022

Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022

April 25, 2022

Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma

April 13, 2022

Exelixis Announces Charles Cohen, Ph.D., to Retire from Board of Directors

April 12, 2022

Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

March 24, 2022

Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer

March 13, 2022

Exelixis To Webcast Fireside Chats as Part of Investor Conferences in March

March 1, 2022

Exelixis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

February 16, 2022

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

February 13, 2022

Exelixis to Release Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 17, 2022

February 2, 2022

Exelixis to Webcast Virtual Fireside Chat as Part of the Guggenheim Healthcare Talks Oncology Day on February 9, 2022

February 1, 2022

Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022

January 17, 2022

Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022

January 8, 2022

Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor

January 5, 2022

Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma

January 4, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 11 decks. Every deck is listed under its year.